




Patent Docket P1150R2C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Avi J. Ashkenazi et al.</p> <p>Serial No.: 10/713,391</p> <p>Filed: November 14, 2003</p> <p>For: DNA 19355 Polypeptide, A Tumor Necrosis Factor Homolog</p>	<p>Group Art Unit: 1615</p> <p>Examiner: to be assigned</p> <p>Confirmation No: 1592</p> <p>Customer No: 09157</p> <hr/> <p style="text-align: center;">CERTIFICATE OF EXPRESS MAILING</p> <p>Express Mail Number: <u>EV 351 932 097 US</u></p> <p><small>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".</small></p> <p style="text-align: right;">May 12, 2004  Diane L. Marschang</p>
---	--

AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This document is responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 31, 2004 for which a two-month period for response was given. Entry of the amendment below is respectfully requested prior to examination on the merits.

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.